Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent advances in structural types and medicinal chemistry of PARP-1 inhibitors
Ling Yu, Zhiwei Yan, Youde Wang, et al.
Medicinal Chemistry Research (2022) Vol. 31, Iss. 8, pp. 1265-1276
Closed Access | Times Cited: 11

Showing 11 citing articles:

Design, synthesis and biological evaluation of matrine contains benzimidazole derivatives as dual TOPOI and PARP inhibitors for cancer therapy
Gan Qiu, Junwei Xie, Fan Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 270, pp. 116348-116348
Closed Access | Times Cited: 6
Structurally Diverse Tetrahydroxanthone Analogues from Paraconiothyrium Sp. Ac31 with Pyroptosis Induction Through Targeted Inhibition of Parp1 in Hepatocellular Carcinoma Cells
Mengke Zhang, Qingqing Hu, Liming He, et al.
(2025)
Closed Access
Structurally Diverse Tetrahydroxanthone Analogues from Paraconiothyrium Sp. Ac31 with Pyroptosis Induction Through Targeted Inhibition of Parp1 in Hepatocellular Carcinoma Cells
You‐Sheng Cai, Mengke Zhang, Qingqing Hu, et al.
(2025)
Closed Access
Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiency
Peng Yuan, Nan Ma, Binghe Xu
Medicinal Research Reviews (2024) Vol. 44, Iss. 6, pp. 2774-2792
Open Access | Times Cited: 4
Advances in Development of Selective Antitumor Inhibitors That Target PARP-1
Fang Liu, Jia‐Shu Chen, Xiangqian Li, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 24, pp. 16464-16483
Closed Access | Times Cited: 11
PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer
Moriah Cunningham, Matthew J. Schiewer
Cancer Research (2024) Vol. 84, Iss. 13, pp. 2049-2059
Open Access | Times Cited: 1
Exploring heterometallic bridged Pt(II)-Zn(II) complexes as potential antitumor agents
Tanja Soldatović, Biljana Šmit, Emina Mrkalić, et al.
Journal of Inorganic Biochemistry (2022) Vol. 240, pp. 112100-112100
Closed Access | Times Cited: 7
Discovery of novel 2,3,4,5-tetrahydrospiro[benzo[c]azepine-1,1’-cyclohexan]-5-ol derivatives as PARP-1 inhibitors
Ling Yu, Jianhui Li, Jü Zhu, et al.
BMC Chemistry (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 2
Design and Synthesis of Benzo-Spirocyclic Derivatives as Potent PARP-1 Inhibitors
Shu Jia, Ling Yu, Jingyi Zhao, et al.
Russian Journal of Bioorganic Chemistry (2024) Vol. 50, Iss. 1, pp. 162-169
Closed Access
Synthesis of Novel Benzopril‐Derived Trizole Compounds Assisted by Ultrasound: In Vitro and In Silico Analysis for Potential Anticancer Properties
Ashok Ettam, L. Vaikunta Rao, Guniganti Balakishan, et al.
Chemistry & Biodiversity (2024)
Closed Access
Liposome Formulations for the Strategic Delivery of PARP1 Inhibitors: Development and Optimization
Carlota J.F. Conceição, Elin Moe, Paulo A. Ribeiro, et al.
Nanomaterials (2023) Vol. 13, Iss. 10, pp. 1613-1613
Open Access | Times Cited: 1
Page 1

Scroll to top